JPMorgan Chase & Co. trimmed its stake in shares of Luminex Co. (NASDAQ:LMNX) by 46.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,983 shares of the medical instruments supplier’s stock after selling 24,075 shares during the period. JPMorgan Chase & Co.’s holdings in Luminex were worth $566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its holdings in Luminex by 1.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,640 shares of the medical instruments supplier’s stock valued at $668,000 after purchasing an additional 402 shares during the period. Pinebridge Investments L.P. grew its holdings in Luminex by 8.3% in the second quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock valued at $111,000 after purchasing an additional 405 shares during the period. Comerica Bank grew its holdings in Luminex by 1.4% in the second quarter. Comerica Bank now owns 41,824 shares of the medical instruments supplier’s stock valued at $866,000 after purchasing an additional 583 shares during the period. New York State Common Retirement Fund grew its holdings in Luminex by 1.4% in the second quarter. New York State Common Retirement Fund now owns 44,200 shares of the medical instruments supplier’s stock valued at $934,000 after purchasing an additional 599 shares during the period. Finally, Voya Investment Management LLC grew its holdings in Luminex by 1.9% in the second quarter. Voya Investment Management LLC now owns 92,553 shares of the medical instruments supplier’s stock valued at $1,955,000 after purchasing an additional 1,737 shares during the period. 79.16% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director G Walter Loewenbaum II sold 39,456 shares of Luminex stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $20.40, for a total transaction of $804,902.40. Following the transaction, the director now owns 651,736 shares in the company, valued at $13,295,414.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 131,698 shares of company stock worth $2,761,201 over the last ninety days. Corporate insiders own 6.90% of the company’s stock.

LMNX has been the topic of several research analyst reports. BTIG Research assumed coverage on Luminex in a report on Friday, January 5th. They issued a “buy” rating and a $24.00 price objective on the stock. BidaskClub lowered Luminex from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. TheStreet raised Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $21.00 price target on shares of Luminex in a research note on Friday, October 20th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.80.

Shares of Luminex Co. (NASDAQ:LMNX) opened at $20.56 on Wednesday. The stock has a market capitalization of $912.81, a P/E ratio of 31.15, a PEG ratio of 1.98 and a beta of 0.19. Luminex Co. has a 12 month low of $17.68 and a 12 month high of $22.42.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.06. The firm had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.21 earnings per share. research analysts predict that Luminex Co. will post 0.49 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, January 12th. Stockholders of record on Friday, December 22nd were paid a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend was Thursday, December 21st. Luminex’s dividend payout ratio is presently 36.36%.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Has $566,000 Position in Luminex Co. (LMNX)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/01/17/jpmorgan-chase-co-has-566000-position-in-luminex-co-lmnx.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.